Older, younger patients with metastatic pancreatic cancer have similar survival
the ONA take:
Older patients metastatic pancreatic cancer are less likely to receive chemotherapy and receive fewer agents yet have similar overall survival compared with younger patients with metastatic disease, according to a recent study published online ahead of print in the Journal of Geriatric Oncology.
For the study, researchers at Fox Chase Cancer Center in Philadelphia, PA, sought to compare patterns of care and outcomes of patients with metastatic pancreatic cancer who are less than 65 years of age with those older than 65 years of age treated at their institution.
The researchers analyzed the medical records of 579 patients who were treated between 2000 and 2010. Results showed that patients older than 65 years were less likely to receive any chemotherapy for their cancer. In addition, those over 65 who were treated were less likely to receive more than 1 agent.
Researchers found that survival was comparable between the two cohorts. In both groups, a higher number of treatment agents and lung metastatases was associated with longer overall survival, while liver metastates were associated with worse survival.
The findings suggest that older patients with metastatic pancreatic cancer with good performance status should be encouraged to enroll onto clinical trials.
Older patients metastatic pancreatic cancer are less likely to receive chemotherapy compared with younger patients with metastatic disease.
- Prehabilitation Program Improves Preoperative Fitness in Patients With Colorectal Cancer
- Acupuncture Improves Postoperative Symptoms in Women Undergoing Surgery for Breast Cancer
- Combination of Gemcitabine and New CHK1 Inhibitor Is Effective in Soft Tissue Sarcomas
- Alcohol Consumption, Particularly White Wine, Associated With Increased Risk of Melanoma
- In HER2+ Breast Cancer, Higher TIL Levels Associated With Improved OS
- Exercise is as Effective in Treating Metastatic Prostate Cancer as Medication
- Walnut Consumption Changes Gut Microbiome, Decreases Growth of Colon Cancer in Mice
- Vaccine Enters Phase I Study for Safety and Effectiveness in Multiple Myeloma
- Timing Chemotherapy Administration to Circadian Rhythm Improves Drug Effectiveness
- New Therapy Blocks Breast Cancer Cells From Entering and Hiding in Bone Marrow to Form Latent Metastases
- Costs, Complications Higher for Women Who Undergo Second Surgery After BCS
- Omitting RT in Certain Older Women With Early Breast Cancer is Safe
- Fluorescent Nanoparticles Represent Novel Detection Method of HER2 Expression
- Assessment of Stromal Features in DCIS Requires Robustness
- Profile of Tivantinib and its Potential in the Treatment of Hepatocellular Carcinoma: the evidence to date
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|